StockNews.com Initiates Coverage on IRIDEX (NASDAQ:IRIX)

Stock analysts at StockNews.com assumed coverage on shares of IRIDEX (NASDAQ:IRIX) in a research note issued on Monday. The firm set a “hold” rating on the medical equipment provider’s stock.

IRIDEX Price Performance

Shares of NASDAQ:IRIX opened at $1.66 on Monday. IRIDEX has a 12 month low of $1.27 and a 12 month high of $3.65. The stock has a market cap of $27.62 million, a P/E ratio of -2.48 and a beta of 0.82. The company has a current ratio of 1.54, a quick ratio of 0.85 and a debt-to-equity ratio of 0.55. The company has a 50 day moving average of $1.72 and a 200 day moving average of $1.79.

IRIDEX (NASDAQ:IRIX) last announced its earnings results on Tuesday, November 12th. The medical equipment provider reported ($0.12) earnings per share (EPS) for the quarter. IRIDEX had a negative net margin of 22.79% and a negative return on equity of 192.95%. The company had revenue of $11.58 million for the quarter. During the same period in the previous year, the firm posted ($0.11) EPS.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.